Riddell Alastair 4
4 · AzurRx BioPharma, Inc. · Filed Mar 13, 2020
Insider Transaction Report
Form 4
Riddell Alastair
Director
Transactions
- Award
Common Stock
2020-03-11$4.74/sh+770$3,650→ 100,770 total - Award
Common Stock
2020-03-11$3.99/sh+2,507$10,003→ 103,541 total - Award
Common Stock
2020-03-11$4.74/sh+264$1,251→ 101,034 total - Award
Common Stock
2020-03-11$3.63/sh+2,755$10,001→ 106,296 total - Award
Common Stock
2020-03-11$0.60/sh+14,584$8,750→ 123,635 total - Award
Common Stock
2020-03-11$1.04/sh+8,414$8,751→ 132,049 total
Footnotes (12)
- [F1]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2016.
- [F10]Based on the stock price at September 30, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
- [F11]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2019.
- [F12]Based on the stock price at December 31, 2019 at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
- [F2]Based on the stock price at September 30, 2016, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
- [F3]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2016.
- [F4]Based on the stock price at December 31, 2016 at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
- [F5]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors during 2016.
- [F6]Based on the stock price on April 21, 2017, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
- [F7]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2017.
- [F8]Based on the stock price at December 31, 2017, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
- [F9]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2019.